MARKET

RNAZ

RNAZ

Transcode Therapeutics Inc
NASDAQ
4.970
+0.420
+9.23%
After Hours: 4.830 -0.14 -2.82% 18:14 06/26 EDT
OPEN
4.755
PREV CLOSE
4.550
HIGH
5.17
LOW
4.568
VOLUME
16.52K
TURNOVER
--
52 WEEK HIGH
20.99
52 WEEK LOW
3.820
MARKET CAP
4.72M
P/E (TTM)
-0.1020
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNAZ last week (0615-0619)?
Weekly Report · 6d ago
TransCode Therapeutics publishes investor presentation on RNA therapeutics, cancer vaccines and oncolytic immunotherapy platforms
PUBT · 06/18 15:49
TransCode Highlights Progress of Lead RNA Cancer Therapeutic
TipRanks · 06/18 12:39
Weekly Report: what happened at RNAZ last week (0608-0612)?
Weekly Report · 06/15 09:24
Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch
NASDAQ · 06/11 03:03
Weekly Report: what happened at RNAZ last week (0601-0605)?
Weekly Report · 06/08 09:22
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
Barchart · 06/08 07:04
Transcode reports results from Phase 1a dose escalation trial with TTX-MC138
TipRanks · 06/03 13:30
More
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Webull offers Transcode Therapeutics Inc stock information, including NASDAQ: RNAZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAZ stock methods without spending real money on the virtual paper trading platform.